Cardio Diagnostics Holdings, Inc. (CDIO) Spending and interest coverage
- R&D / revenue · 12 months: Value 4405.52%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 677.72%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -525.07×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 4405.52% | Research and development expense / revenue. Period ending 2026-06-30. $636.60K ÷ $14.45K × 100 ≈ 4405.52% |
| Stock-based compensation / revenue · 12 months | 677.72% | Share-based compensation / revenue. Period ending 2026-06-30. $97.93K ÷ $14.45K × 100 ≈ 677.72% |
| Interest coverage · 12 months | -525.07× | Operating income ÷ reported interest expense. $-6.46M ÷ $12.30K ≈ -525.07× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 636.60K USD | Research and Development Expense |
| Revenue | 14.45K USD | |
| Stock-based compensation | 97.93K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -6.46M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 12.30K USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $636.60K | $14.45K | $97.93K | $-6.46M | $12.30K | 4405.52% | 677.72% | -525.07× | Reported |
| 2026-03-31 | $652.20K | $16.57K | $104.36K | $-6.64M | $13.55K | 3937.24% | 629.98% | -489.95× | Reported |
| 2025-12-31 | $641.21K | $14.82K | $110.23K | $-6.48M | $14.80K | 4325.21% | 743.58% | -438.08× | Reported |
| 2025-09-30 | $360.10K | $15.78K | $108.57K | $-6.54M | $15.64K | 2281.73% | 687.92% | -418.09× | Reported |
| 2025-06-30 | $176.30K | $19.51K | $106.42K | $-6.23M | $16.39K | 903.78% | 545.56% | -380.46× | Reported |
| 2025-03-31 | $20.48K | $19.90K | $102.38K | $-5.84M | $17.51K | 102.93% | 514.40% | -333.36× | Reported |
| 2024-12-31 | $29.13K | $34.89K | $2.59M | $-8.37M | $18.64K | 83.48% | 7426.68% | -448.81× | Reported |
| 2024-09-30 | $30.86K | $35.69K | $2.63M | $-8.39M | $111.61K | 86.47% | 7371.53% | -75.18× | Reported |
| 2024-06-30 | $64.32K | $39.14K | $2.68M | $-8.43M | $678.12K | 164.34% | 6847.91% | -12.43× | Reported |
| 2024-03-31 | $69.36K | $32.99K | $3.79M | $-9.70M | $1.72M | 210.22% | 11501.46% | -5.62× | Reported |
| 2023-12-31 | $145.18K | $17.07K | $1.28M | $-7.24M | $6.74M | 850.76% | 7496.47% | -1.08× | Reported |
| 2023-09-30 | $168.78K | $12.71K | $1.22M | $-8.08M | (m) | 1328.43% | 9581.05% | (m) | (m) |
| 2023-06-30 | $133.26K | $2.67K | $1.15M | $-7.79M | (m) | 4981.64% | 42813.94% | (m) | (m) |
| 2023-03-31 | $125.98K | $950.00 | $4.00K | (m) | (m) | 13261.37% | 421.05% | (m) | (m) |
| 2022-12-31 | $40.45K | $950.00 | $0.00 | $-4.55M | (m) | 4257.68% | 0.00% | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |